Developments in the scientific and clinical understanding of the spondyloarthritides

Arthritis Research and Therapy

Volumn 11, Issue 1, 2009, Pages

  Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ANTIINFLAMMATORY ACTIVITY; AXIAL SPONDYLOARTHRITIDES; BACKACHE; CHRONIC PAIN; DELAYED DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DRUG EFFICACY; ENTERITIS; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; OSSIFICATION; PATHOGENESIS; PRIMARY MEDICAL CARE; PSORIATIC ARTHRITIS; RADIOGRAPHY; REVIEW; SACROILIITIS; SPONDYLOARTHROPATHY; SYMPTOM; UVEITIS; GENETIC PREDISPOSITION; IMMUNOLOGY; SPONDYLARTHRITIS;

GENETIC PREDISPOSITION TO DISEASE; HLA-B27 ANTIGEN; HUMANS; SPONDYLARTHRITIS;

EID: 60549114195     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2562     Document Type: Review

References (59)

1. Sieper J Rudwaleit M Khan MA Braun J Concepts and epidemiology of spondyloarthritis Best Pract Res Clin Rheumatol 2006, 20:401-417 10.1016/ j.berh.2006.02.001 16777573
2. Dougados M Linden van der S Juhlin R Huitfeldt B Amor B Calin A Cats A Dijkmans B Olivieri I Pasero G Vegs E Zeioller H The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy Arthritis Rheum 1991, 34:1218-1227 10.1002/art.1780341003 1930310
3. Rudwaleit M Khan MA Sieper J The challenge of diagnosis and classification in early ankylosing spondylitis: Do we need new criteria? Arthritis Rheum 2005, 52:1000-1008 10.1002/art.20990 15818678
4. Taylor W Gladman D Helliwell P Marchesoni A Mease P Mielants H Classification criteria for psoriatic arthritis: Development of new criteria from a large international study Arthritis Rheum 2006, 54:2665-2673 10.1002/art.21972 16871531
5. Helliwell PS Porter G Taylor WJ Polyarticular psoriatic arthritis is more like oligoarticular psoriatic arthritis, than rheumatoid arthritis Ann Rheum Dis 2007, 66:113-117 10.1136/ard.2006.054288 16840501
6. Kruithof E Baeten D De Rycke L Vandooren B Foell D Roth J Canete JD Boots AM Veys EM De Keyser F Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis Arthritis Res Ther 2005, 7:R569-580 1174942 15899044 10.1186/ar1698
7. Amor B Dougados M Mijiyawa M [Criteria of the classification of spondylarthropathies] Rev Rhum Mal Osteoartic 1990, 57:85-89 2181618
8. Braun J Bollow M Remlinger G Eggens U Rudwaleit M Distler A Sieper J Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors Arthritis Rheum 1998, 41:58-67 10.1002/ 1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G 9433870
9. Braun J Sieper J Ankylosing spondylitis Lancet 2007, 369:1379-1390 10.1016/S0140-6736(07)60635-7 17448825
10. Feldtkeller E Khan MA Heijde van der D Linden van der S Braun J Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis Rheumatol Int 2003, 23:61-66 12634937
11. Haibel H Brandt HC Song IH Brandt A Listing J Rudwaleit M Sieper J No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial Ann Rheum Dis 2007, 66:419-421 10.1136/ ard.2006.054098 16901959
12. Linden van der S Valkenburg HA Cats A Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria Arthritis Rheum 1984, 27:361-368 10.1002/art.1780270401 6231933
13. Oostveen J Prevo R den Boer J Laar van de M Early detection of sacroiliitis on magnetic resonance imaging and subsequent development of sacroiliitis on plain radiography. A prospective, longitudinal study J Rheumatol 1999, 26:1953-1958 10493676
14. Haibel H Rudwaleit M Listing J Heldmann F Wong RL Kupper H Braun J Sieper J Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two Arthritis Rheum 2008, 58:1981-1991 10.1002/art.23606 18576337
15. Underwood MR Dawes P Inflammatory back pain in primary care Br J Rheumatol 1995, 34:1074-1077 10.1093/rheumatology/34.11.1074 8542211
16. Heijde van der D Calin A Dougados M Khan MA Linden van der S Bellamy N Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis J Rheumatol 1999, 26:951-954 0229426
17. Braun J Baraliakos X Golder W Brandt J Rudwaleit M Listing J Bollow M Sieper J Heijde Van Der D Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: Evaluation of a new scoring system Arthritis Rheum 2003, 48:1126-1136 10.1002/art.10883 12687557
18. Wanders AJ Landewe RB Spoorenberg A Dougados M Linden van der S Mielants H Tempel van der H Heijde van der DM What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter Arthritis Rheum 2004, 50:2622-2632 10.1002/ art.20446 15334477
19. Anderson JJ Baron G Heijde van der D Felson DT Dougados M Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis Arthritis Rheum 2001, 44:1876-1886 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F 11508441
20. Rudwaleit M Listing J Brandt J Braun J Sieper J Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis Ann Rheum Dis 2004, 63:665-670 1755042 15037444 10.1136/ard.2003.016386
21. Garrett S Jenkinson T Kennedy LG Whitelock H Gaisford P Calin A A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index J Rheumatol 1994, 21:2286-2291 7699630
22. Zochling J Heijde van der D Burgos-Vargas R Collantes E Davis JC Jr Dijkmans B Dougados M Géher P Inman RD Khan MA Kvien TK Leirisalo-Repo M Olivieri I Pavelka K Sieper J Stucki G Sturrock RD Linden van der S Wendling D Böhm H van Royen BJ Braun J 'ASsessment in AS' international working group; European League Against Rheumatism ASAS/EULAR recommendations for the management of ankylosing spondylitis Ann Rheum Dis 2006, 65:442-452 10.1136/ard.2005.041137 16126791
23. Braun J Zochling J Baraliakos X Alten R Burmester G Grasedyck K Brandt J Haibel H Hammer M Krause A Mielke F Tony HP Ebner W Gömör B Hermann J Zeidler H Beck E Baumgaertner M Sieper J Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: A multicentre randomized controlled trial Ann Rheum Dis 2006, 65:1147-1153 10.1136/ard.2006.052878 16606646
24. Chen J Liu C Sulfasalazine for ankylosing spondylitis Cochrane Database Syst Rev 2005, 2:CD004800 15846731
25. Chen J Liu C Methotrexate for ankylosing spondylitis Cochrane Database Syst Rev 2004, 3:CD004524 15266537
26. Haibel H Rudwaleit M Braun J Sieper J Six months open label trial of leflunomide in active ankylosing spondylitis Ann Rheum Dis 2005, 64:124-126 1755172 15608310 10.1136/ard.2003.019174
27. Song IH Poddubnyy DA Rudwaleit M Sieper J Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs Arthritis Rheum 2008, 58:929-938 10.1002/art.23275 18383378
28. Wanders A Heijde D Landewe R Behier JM Calin A Olivieri I Zeidler H Dougados M Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial Arthritis Rheum 2005, 52:1756-1765 10.1002/art.21054 15934081
29. Sieper J Appel H Braun J Rudwaleit M Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes Arthritis Rheum 2008, 58:649-656 10.1002/art.23260 18311819
30. Braun J Brandt J Listing J Zink A Alten R Golder W Gromnica-Ihle E Kellner H Krause A Schneider M Sörensen H Zeidler H Thriene W Sieper J Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial Lancet 2002, 359:1187-1193 10.1016/S0140-6736(02)08215-6 11955536
31. Davis JC Jr Heijde Van Der D Braun J Dougados M Cush J Clegg DO Kivitz A Fleischmann R Inman R Tsuji W Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial Arthritis Rheum 2003, 48:3230-3236 10.1002/art.11325 14613288
32. Heijde van der D Kivitz A Schiff MH Sieper J Dijkmans BA Braun J Dougados M Reveille JD Wong RL Kupper H Davis JC Jr ATLAS Study Group Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum 2006, 54:2136-2146 10.1002/ art.21913 16802350
33. Braun J Landewe R Hermann KG Han J Yan S Williamson P Heijde van der D Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study Arthritis Rheum 2006, 54:1646-1652 10.1002/art.21790 16646033
34. Sieper J Baraliakos X Listing J Brandt J Haibel H Rudwaleit M Braun J Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab Rheumatology (Oxford) 2005, 44:1525-1530 10.1093/rheumatology/kei046 16091396
35. Heiberg MS Nordvag BY Mikkelsen K Rodevand E Kaufmann C Mowinckel P Kvien TK The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: A six-month, longitudinal, observational, multicenter study Arthritis Rheum 2005, 52:2506-2512 10.1002/art.21209 16052584
36. Baraliakos X Listing J Brandt J Rudwaleit M Sieper J Braun J Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Arthritis Res Ther 2005, 7:R439-444 1174938 15899030 10.1186/ ar1693
37. Breban M Ravaud P Claudepierre P Baron G Henry YD Hudry C Euller-Ziegler L Pham T Solau-Gervais E Chary-Valckenaere I Marcelli C Perdriger A Le Loët X Wendling D Fautrel B Fournié B Combe B Gaudin P Jousse S Mariette X Baleydier A Trape G Dougados M French Ankylosing Spondylitis Infliximab Network Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one-year randomized controlled trial comparing systematic versus on-demand treatment Arthritis Rheum 2008, 58:88-97 10.1002/art.23167 18163509
38. Braun J Baraliakos X Listing J Davis J Heijde van der D Haibel H Rudwaleit M Sieper J Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents Arthritis Rheum 2007, 57:639-647 10.1002/art.22669 17471540
39. Braun J Baraliakos X Listing J Sieper J Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept Arthritis Rheum 2005, 52:2447-2451 10.1002/art.21197 16052578
40. Rudwaleit M Rodevand E Holck P Vanhoof J Kron M Kary S Kupper H Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study Ann Rheum Dis 2008
41. Kavanaugh AF Ritchlin CT Systematic review of treatments for psoriatic arthritis: An evidence based approach and basis for treatment guidelines J Rheumatol 2006, 33:1417-1421 16724373
42. Rudwaleit M Schwarzlose S Hilgert ES Listing J Braun J Sieper J MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis Ann Rheum Dis 2008, 67:1276-1281 10.1136/ard.2007.073098 18006539
43. Braun J Davis J Dougados M Sieper J Linden van der S Heijde van der D First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis Ann Rheum Dis 2006, 65:316-320 10.1136/ard.2005.040758 16096329
44. Barkham N Keen H Coates L O'Connor P Hemsor EMA Fraser AD Cawkwell P McGonagle D Emery P A randomised controlled trial of infliximab shows clinical and MRI efficacy in patients with HLA-B27 positive very early ankylosing spondylitis [abstract] Arthritis Rheum 2007, 56(Supplement L11)
45. Cruickshank B Lesions of cartilaginous joints in ankylosing spondylitis J Pathol Bacteriol 1956, 71:73-84 10.1002/path.1700710111 13307336
46. McGonagle D Gibbon W Emery P Classification of inflammatory arthritis by enthesitis Lancet 1998, 352:1137-1140 10.1016/S0140-6736(97)12004-9 9798608
47. Maksymowych WP Ankylosing spondylitis - at the interface of bone and cartilage J Rheumatol 2000, 27:2295-2301 11036819
48. Appel H Kuhne M Spiekermann S Kohler D Zacher J Stein H Sieper J Loddenkemper C Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: Evaluation of the bone-cartilage interface and subchondral bone marrow Arthritis Rheum 2006, 54:1805-1813 10.1002/ art.21907 16736521
49. Diarra D Stolina M Polzer K Zwerina J Ominsky MS Dwyer D Korb A Smolen J Hoffmann M Scheinecker C Heide van der D Landewe R Lacey D Richards WG Schett G Dickkopf-1 is a master regulator of joint remodeling Nat Med 2007, 13:156-163 10.1038/nm1538 17237793
50. Lories RJ Derese I De Bari C Luyten FP Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondyloarthritis Arthritis Rheum 2007, 56:489-497 10.1002/art.22372 17265484
51. Heijde van der D Landewe R Einstein S Ory P Vosse D Ni L Lin SL Tsuji W Davis JC Jr Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept Arthritis Rheum 2008, 58:1324-1331 10.1002/art.23471 18438853
52. Brewerton DA Hart FD Nicholls A Caffrey M James DC Sturrock RD Ankylosing spondylitis and HL-A 27 Lancet 1973, 1:904-907 10.1016/ S0140-6736(73)91360-3 4123836
53. Sieper J Braun J Kingsley GH Report on the Fourth International Workshop on Reactive Arthritis Arthritis Rheum 2000, 43:720-734 10.1002/ 1529-0131(200004)43:4<720::AID-ANR2>3.0.CO;2-8 10765916
54. Ugrinovic S Mertz A Wu P Braun J Sieper J A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis J Immunol 1997, 159:5715-5723 9548516
55. Turner MJ Delay ML Bai S Klenk E Colbert RA HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: Implications for the pathogenesis of spondylarthritis-like disease Arthritis Rheum 2007, 56:215-223 10.1002/art.22295 17195225
56. Atagunduz P Appel H Kuon W Wu P Thiel A Kloetzel PM Sieper J HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis Arthritis Rheum 2005, 52:892-901 10.1002/art.20948 15751060
57. Khan MA Mathieu A Sorrentino R Akkoc N The pathogenetic role of HLA-B27 and its subtypes Autoimmun Rev 2007, 6:183-189 10.1016/ j.autrev.2006.11.003 17289555
58. Brown MA Human leucocyte antigen-B27 and ankylosing spondylitis Intern Med J 2007, 37:739-740 10.1111/j.1445-5994.2006.01285.x 17908085
59. Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC) Burton PR Clayton DG Cardon LR Craddock N Deloukas P Duncanson A Kwiatkowski DP McCarthy MI Ouwehand WH Samani NJ Todd JA Donnelly P Barrett JC Davison D Easton D Evans DM Leung HT Marchini JL Morris AP Spencer CC Tobin MD Attwood AP Boorman JP Cant B Everson U Hussey JM Jolley JD Knight AS Koch K et al Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants Nat Genet 2007, 39:1329-1337 10.1038/ng.2007.17 17952073